Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Amylin Stories

2012-04-09 06:24:33

NEW YORK, April 9, 2012 /PRNewswire/ -- Carl C. Icahn today issued the following statement regarding Amylin Pharmaceuticals, Inc.: The revelation of the Bristol-Myers bid, as well as the Board's failure to disclose it and its subsequent issuance of 10% of the company at $15.62 per share on March 8th and its issuance of options to executive officers at $16.02 per share on March 6th (including 300,000 shares to President, CEO and Board member Daniel Bradbury), constitutes a dramatic...

2012-04-04 02:29:54

NEW YORK, April 4, 2012 /PRNewswire/ -- Carl C. Icahn today issued the following open letter to the board of directors of Amylin Pharmaceuticals, Inc.: CARL C. ICAHN767 Fifth Avenue, 47th FloorNew York, New York 10153 April 4, 2012 Amylin Pharmaceuticals, Inc.9360 Towne Centre DriveSan Diego, California 92121 Attention: Board of Directors Re: The reports of your rejection of a $3.5 billion offer from Bristol-Myers Squibb Ladies and Gentlemen: As one of Amylin's largest shareholders, I...

2012-04-03 02:27:01

SAN DIEGO, April 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in pediatric and adult patients with rare forms of lipodystrophy. The rolling BLA submission was initiated in December 2010 with the clinical and...

2012-03-23 02:22:49

SAN DIEGO and INDIANAPOLIS, March 23, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization to BYETTA® (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. "The...

2012-03-08 08:01:00

SAN DIEGO, March 8, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock. The gross proceeds to Amylin from this offering are expected to be approximately $203.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Amylin. The offering is expected to close on or about March 13, 2012, subject to customary...

2012-03-08 07:00:00

SAN DIEGO, March 8, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 14, 2012 at 11:15 a.m. ET / 8:15 a.m. PT. David Maggs, M.D., vice president, medical research and development at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be...

2012-03-07 15:15:00

SAN DIEGO, March 7, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Credit Suisse Securities (USA) LLC is acting as sole book-running manager and underwriter in this offering. A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A final...

2012-02-29 07:00:00

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is participating in the fifth annual international Rare Disease Day to demonstrate the Company's support for patients and families who are impacted by rare diseases. Celebrated around the world today, Rare Disease Day aims to raise awareness of the more than 7,000 known rare diseases and the effects of these diseases on patients' lives, and to provide a platform of unity for...

2012-02-09 15:15:00

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Leerink Swann 2012 Global Healthcare Conference in New York on Thursday, February 16, 2012 at 2:00 p.m. ET / 11:00 a.m. PT. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a...

2012-02-06 15:41:00

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011. Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million. Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GAAP operating income of $22.9 million for the same period in 2010. Full year non-GAAP...